Search Results
PSCI 22-114: A PHASE 2/3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NKTR-255VS PLACEBO FOLLOWINGCD-19 DIRECTED CAR-T THERAPYIN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA.
This is a drug study that will evaluate how well the investigational drug works compared to a placebo following CAR-T cell therapy. Participants will be required to keep all your scheduled visits, receive drug treatment, blood draws, imaging, and possibly a tumor biopsy.
Participants will be required to receive the study treatments including CAR-T infusion, blook tests, imaging, tumor biopsy, and study medications.
Received standard of care therapy with axi-cel or liso-cel (Stage 1 and Stage 2), or tisa-cel (Stage 2 only)
Received lymphodepleting chemotherapy regimen according to the respective FDA (or SmPC) label for CAR-T cell therapy.
Fluorodeoxyglucose (FDG)-avid disease on PET imaging within 30 days prior to CAR-T cell infusion
FDG avid lesion(s) on PET/CT scan following bridging therapy and prior to lymphodepletion, where applicable.
Prior treatment with any CD19-directed CAR-T cell therapy other than the treatment planned per Inclusion Criterion 2.
For allogeneic hematopoietic cell transplant recipients, active graft versus host disease (GVHD) and/or systemic GVHD therapy during screening or up to 30 days prior to leukapheresis.
Known active hepatitis B (detectable hepatitis B DNA) or hepatitis C (detectable hepatitis C RNA).
Known human immunodeficiency virus (HIV) infection
VIBRANT: VIB4920 for Active Lupus Nephritis
A randomized placebo-controlled study to evaluate the efficacy and safety of VIB4920 in study participants with active lupus nephritis
Patients come for in-person visits at the Penn State Hershey main hospital location. There will be blood draws, physical exams, and questionnaires spread out across 60 weeks.
Systemic lupus erythematosus
Transplant
What’s in a grammar? A microcomparative study of negation in American Englishes
In contexts where people speak different dialects of the same language, how much overlap is there between the dialects, and what are the genuine grammatical differences? This study explores this question through a series of three experiments examining how people from three different dialects understand a variety of negative sentences (e.g., I didn't eat nothing). The results will contribute to our understanding of linguistic diversity.
Participants will sit at a computer and have their eye movements tracked by a camera as they read or listen to sentences and look at pictures on the screen.
$15 per hour
not 18 or older
Vernacular Feature Comprehension and Perception in Persons with Aphasia
This study investigates whether persons with aphasia understand and process sentences with vernacular features in a manner similar to more typical populations. Participants will rate sentences on their naturalness and on whether they make sense, and they will also read sentences while we track their eye movements.
2. Sustained stroke more than 6 months prior to consent
3. Native speakers of English
4. Completed at least a high school education
5. Normal or corrected-to-normal vision and hearing
2. An active medical condition that could compromise participation (e.g., cancer undergoing acute treatment)
3. Taking medications that are known to exert significant effects on cognitive processes
4. Do not meet the above inclusionary criteria
Using ERPs and eye-tracking to study language learning and processing in adult learners.
In an increasingly global environment, both within the US and abroad, the ability to rapidly gain native-like linguistic competence is a critical asset. The ability to use an L2 in a way that is both expected and recognized by its native speakers is important both to the broad public, and to specific sectors, such as military personnel, that must develop native-like competence in a foreign language in a limited amount of time. The studies conducted under this IRB protocol will examine how learners/speakers of a second language acquire and process multi-word units (e.g., carry a business; run a store) in their second language, and how knowledge from the first language might influence the learning and processing of multi-word units in a second language.
Participants will complete a number of simple tasks on a computer in English and/or in Spanish (depending on language background).
$12/hour (behavioral sessions); $18/hour (EEG sessions); $20 bonus at completion of study when at least 3 behavioral sessions or 2 EEG sessions are required.
Not fluent in other languages
No history of neurological or language disorders
Normal or normal-to-corrected vision
Right-handed
Older than 45 years old
Left-handed or ambidextrous
A history of neurological disorders or language disorders
CHARM II: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts: A Prospective, Randomized, Double-blind, Multi-center Clinical Trial
This study seeks to verify the findings of the CHARM I pilot study by conducting a multi-center clinical trial. We hypothesize that: • Pancreatic cyst infusion with a specifically designed drug therapy cocktail following normal saline lavage will result in cyst destruction rates that do not significantly differ from those achieved by alcohol-based cyst treatment (ethanol lavage followed by infusion of the same chemotherapeutic cocktail). • The removal of alcohol from the procedure will decrease both serious and minor adverse event rates associated with pancreatic cyst treatment. • There may be molecular markers contained within the fluid of these cystic tumors which identify cysts that are favorable to or resistant to EUS-guided fine needle infusion using this drug combination. As such, we will test all treated cysts for 10 of the best known molecular markers for evaluation in post study analysis. We expect that administering a specifically designed chemotherapeutic cocktail without prior alcohol lavage will result in an equivalent rate of cyst resolution with fewer complications when compared to alcohol. The results of this study will provide important information about the most efficient and safest method for treating premalignant pancreatic cysts, an important step for treating these lesions with a minimally invasive technique and preventing their progression to cancer. Standard alternative treatment options for this patient group (if not taking part in this study) would be ongoing periodic radiographic monitoring with MR or CT imaging waiting for signs of cancer to develop or to consider surgical removal of the affected tissue.
Patients will have to sign the consent form to participate in the trial
Patients with a previously-detected pancreatic cyst(s) 2-5 cm in diameter which are consistent with a mucinous type cyst as per ASGE guidelines including indeterminate type cysts.
Ability to give written informed consent.
Capable of safely undergoing endoscopy with deep sedation or general anesthesia.
Known or suspected pancreatic cancer or pathologic lymphadenopathy.
Cysts with the following high risk features: main pancreatic duct dilation of > 5mm,epithelial type mural nodules , pathologically thick wall/septation (> 2mm)..
Septated cysts with > 4 compartments.
Confirmed acute pancreatitis within the last 3 months.
Effects of Individualist and Collectivist Culture on Emotional Empathy in Counselor Trainees
This research is an attempt to understand the components of empathy and the cultural factors that shape its development. I am seeking about 200 Master's-level counseling students in the U.S. to complete the online survey. The survey takes about 15 minutes to complete, and participants will have chances to win Amazon gift cards and to learn the study results.
over 18-year-old
under 18-year-old
A randomized, open-label, multicentric, two-arm pivotal trial of SonoCloud-9 combined with carboplatin (CBDCA) vs standard of care lomustine (CCNU) or temozolomide (TMZ) in patients undergoing planned resection for first recurrence glioblastoma
We are asking you to take part in this voluntary research study because you have a brain tumor (glioblastoma) that has gotten worse despite first treatment. The purpose of this voluntary research study is to is to learn if the SonoCloud-9 (SC9) implantable device can be used in combination with Carboplatin chemotherapy to help control glioblastoma at recurrence. Neither Sonocloud-9 (SC9) in combination with Carboplatin chemotherapy is not FDA approved.
As part of your routine care, you will be asked to undergo surgery to remove the tumor that has come back. You will be randomized into one of the treatment groups. If you are in the study drug group the surgeon will insert the SonoCloud-9 device (SC9) implant into the skull bone at the end of the tumor resection surgery. If you are in the routine treatment group, the surgeon will close the wound without implanting the SC9 device. The treatment itself will start within 12 to 21 days after the randomization. - If you are in the study drug group you will receive up to 7 doses (every 3 weeks) of Carboplatin at the same time the SonoCloud-9 device is being activated. Further details on the procedures are described below. A brain MRI (Magnetic Resonance Imaging) scan will be performed after the first cycle as part of the research to evaluate opening of the BBB (blood-brain barrier). - If you are in the routine treatment group, you will receive up to 4 doses of Lomustine (every 6 weeks), or, if considered as best appropriate, up to 6 doses of Temozolomide (every 4 weeks). Additional in-person hospital visits or telehealth consultations by video or phone will be performed at regular intervals.
$350.00
Received prior first line therapy
First disease progression
Proven glioblastoma
At least 18 years old
Medical need to be on continued anti-platelet aggregation therapy or coagulation
Peripheral neuropathy
Uncontrolled epilepsy
Known sensitivity/allergy to gadolinium
Active Men's Study
Description: This research study is to assess energetic status, reproductive health, and bone health in a population of young exercising men. Secondarily, this study will also explore how diet, fitness, cardiovascular function, eating behaviors, stress, cognitive function, and sleep related to energy and reproductive outcomes in exercising men. Eligible young men (age 18-35) are those who are generally healthy and either a) exercising or b) not exercising.
There will be essentially 5 study visits - The first visit will include informed consent to take part in the study & completion of questionnaires and measurement of anthropometrics. Visit 2 will include tests of your metabolism, a blood draw, a saliva collection, and assessment of diet and physical activity. Visit 3 will be a short visit for a saliva collection. Visit 4 will include tests of stress (a hair sample), body composition, bone health, aerobic and anaerobic fitness, cognitive testing, and reproductive function. Visit 5 will consist of a results meeting and return of wearable devices and logs.
BMI between 16-29.9 kg/m2
Non-smoker
For sedentary participants: less than 150 minutes of purposeful exercise per week
For exercising participants: at least 150 minutes of purposeful exercise per week (moderate to high intensity aerobic and/or resistance training).
Procedures using contrast material within the past 7 days, including X-rays, MRI scans, CT scans, barium studies, nuclear medicine exams.
Currently a smoker or history of regular smoking
Prostheses
Vasectomy
PSCI-24-092 A PHASE 1, OPEN-LABEL, MULTICENTER STUDY OF JANX007 IN SUBJECTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
This trial will examine different doses of JANX007 to find the safest dose to treat metastatic castration resistant prostate cancer (mCRPC)
Participants will be required to come to all clinic visits, report any symptoms they are having and all medications they are taking, including over the counter medications.
Histologically or cytologically confirmed adenocarcinoma of the prostate
Serum testosterone <50 ng/dL
Documented progression
Progressive mCRPC or intolerance to the most recent therapy
Prior treatment with PSMA-CD3, PSMA-CD28, or other CD3-T cell engaging bispecific antibodies.
Prior solid organ transplant
Use of any herbal products that could decrease PSA levels
Threat of infection, social decision-making, and the autonomic nervous system
The purpose of the study is to test how social decisions are affected by possible risk of infection. We aim to examine how choices in a risky social decision-making situation can influenced by viewing images of infection threat (e.g., person with runny nose) vs. images of neutral scenes or other threatening scenes.
There will be one 90-minute in-person visit. Participants will be asked to have electrodes placed on their skin to record their physiological signals, answer questionnaires, and complete a decision-making task on the computer while looking at different images.
$30
Student at Penn State University Park
English-speaking
No cardiovascular, metabolic, or neurological condition
No diagnosis of COVID-19 within the last 14 days
Not a student at Penn State University Park
Does not speak English
Has cardiovascular, metabolic, or neurological condition
Has/had diagnosis of COVID-19 within the last 14 days
A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)
Participants in the PIVOT-006 study will either receive surgical treatment plus cretostimogene or surgical treatment alone.This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by CG0070 vs TURBT for the treatment of patients with IR-NMIBC.The purpose of this study is to see if cretostimogene can reduce the risk of your bladder cancer returning, or coming back as quickly as if you did not receive cretostimogene. People in the study will continue to be monitored by cystoscopy and pathology to see how long it takes for the cancer to return. Who May Be Eligible to Take Part In This Study: People with: • Bladder Cancer that has not invaded the muscle (Non-Muscle Invasive Bladder Cancer) • Intermediate-Risk Disease • Over 18All Treatment: 18All patients will receive surgical treatment on study as part of Standard-of-Care. 50% of patients will receive cretostimogene in addition to surgical treatment. For patients who do not receive cretostimogene, you will be offered cretostimogene if your bladder cancer recurs. The treatment will be instilled into the bladder through a thin tube called a catheter. This will be done 14 times over an 12-month period. Main Meausure: Patients who have recurrence of bladder cancer after receiving surgery plus cretostimogene compared to patients who receive surgery alone.
if you decide to take part in this study and meet all of the requirements, all patients will receive surgical treatment on study as part of Standard-of-Care. 50% of patients will receive cretostimogene in addition to surgical treatment. For patients who do not receive cretostimogene, you will be offered cretostimogene if your bladder cancer recurs. You will receive 6 treatments, once per week for 6 weeks in a row. The treatment will be instilled into the bladder through a thin tube called a catheter. This will be done 14 times over an 12-month period. There will be up to 16 visits with blood draw and/or urine colelction. As a part of screening, efficacy and follow up for this study, you might have to have cystoscopy ( up to 6), urine cytology (up to 6), TUBRT or vladder mapping or CT urogram over a 3 year month period.
Intermediate-Risk Disease
Is ≥18 years of age on day of signing informed consent.
Demonstrates adequate organ function
Is willing to comply with study mandated cystoscopies, urine cytology, CT urograms, TURBTs/biopsies, and other procedures
Has disease that cannot be completely resected.
Has current or history of muscle-invasive cancer or locally advanced or metastatic bladder cancer
Has a history of High-grade or Low-Grade urothelial cancer
Has received systemic anti-cancer therapy, including investigational agents, within 4 weeks of randomization.
PSCI 23-099 NRG-BR009: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25 (OFSET)
To determine if chemotherapy added to ovarian suppression and endocrine therapy is better than endocrine therapy and ovarian supression alone.
Subjects will be required to keep all study appointments, take the medications as required, have an annual mammogram, inform the study of any over the counter medications they may be taking.
Patients must be premenopausal
The patient must have an ECOG performance status of ≤ 2
Patients may have ipsilateral or contralateral synchronous breast cancer if the highest stage tumor meets entry criteria, and the other sites of disease would not require chemotherapy or HER2-directed therapy.
Patients may have multicentric or multifocal breast cancer if the highest stage tumor meets entry criteria, and the other sites of disease would not require chemotherapy or HER2-directed therapy.
pT4 tumors, including inflammatory breast cancer.
History of ipsilateral or contralateral invasive breast cancer.
Life expectancy of < 10 years due to co-morbid conditions in the opinion of the investigator.
Home Observation of Meals and Environment (HOME) Bytes
This study aims to measure child eating behavior at home. Parents will video record their child eat 3 meals at home using a smart phone device and then take pictures of food storage locations (e.g., fridge, pantry). Videos will be coded for child eating behaviors. Parents will complete baseline and follow-up questionnaires. Children will wear an activity watch (like a Fitbit) for 1 week. In addition to these study procedures, there is an optional urine sample collection for children in order to study urinary metabolites as a marker of diet.
You will be asked to video record your child eating 3 meals at home and to take photos of food storage locations in your home (e.g., fridge, pantry).
$75 and an optional $25 for completing the urine sample collection
Child must have no neurodevelopmental disorder (e.g., ADHD) or learning disabilities (e.g., dyslexia)
Child must not be taking any medications known to influence body weight, taste, food intake, behavior, or blood flow.
Child must be 7-10 years-old at enrollment
The child must speak English
Child is taking cold or allergy medication, or other medications known to influence cognitive function, taste, appetite, or blood flow.
Child has a learning disability, ADD/ADHD, language delays, autism or other neurological or psychological conditions.
Child has a pre-existing medical condition such as type I or type II diabetes, rheumatoid arthritis, Cushing’s syndrome, Down’s syndrome, severe lactose intolerance, Prader-Willi syndrome, HIV, cancer, renal failure, or cerebral palsy.
Child has a highly restrictive diet limiting their ability to consume typical meals due to disordered eating (anorexia, RFID) or severe allergies.
22-124 Main-CAV
To evaluate the effect of cabozantinib in combination with avelumab on OS compared to avelumab alone in patients with mUC who did not progress during first-line platinum-based chemotherapy therapy, i.e. patients who had CR, PR or SD after completion of first line platinum-based chemotherapy.
Patients will be expected to come to all clinic appointments, have labs drawn on the first day of every cycle, take medications as prescribed, return all empty pill bottles and diary, and call the clinic with questions.
Prior first-line treatment must have consisted of 4-6 cycles of 1st-line therapy (platinum-based chemotherapy; gemcitabine-cisplatin, gemcitabine-carboplatin, MVAC or ddMVAC).
No prior immunotherapy with IL-2, IFN-α, or an anti-PD-1, anti-PD-L1, anti-PDL2, anti-CD137, or CTLA-4 antibody (including ipilimumab), or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.
ECOG Performance Status of 0 or 1
Age ≥ 18 years
No known symptomatic central nervous system (CNS) metastases.
No major surgery within 4 weeks prior to randomization.
No palliative radiotherapy within 48 hours prior to patient randomization.
No known cavitating pulmonary lesion(s) or known endobronchial disease manifestation.
A more naturalistic interaction: using back-channeling in smart-speakers to indicate active listening
In this project, we aim to extend the capabilities of smart-speakers (such as Amazon Alexa, Google Home, Siri, etc.) to support more engaging interactions with their users. Specifically, we would like to make the future of smart-speakers more conversational. One of the key aspects in developing a conversation is to be an active listener; showing interest in the speaker and allowing them to extend their turn in talk. In this study we investigate how smart-speakers can become better listeners by incorporating some of the human-human conversational features of active listening. Our question is, how can smart-speakers extend the users' turn in talk by being better listeners?
English speaking individuals
non english-speaking individuals
Elucidating the Necessary Active Components of Training (ENACT) Study
This study will examine the effects of different brain games on cognitive and everyday activities in middle-aged and older adults. Participants will play either 20 or 40 hours of ENACT brain games on a study provided laptop. They will also complete daily surveys on a study-provided mobile phone for the duration of the study. These surveys will take approximately 5-6 minutes to complete per day. The study will last either 6 or 9 months depending on the brain game training time. The study will be done remotely from the comfort of home using study-provided mobile devices. Participants are compensated for their time.
Participants will play either 20 or 40 hours of ENACT brain games on a study provided laptop. They will also complete daily surveys on a study-provided mobile phone for the duration of the study. These surveys will take approximately 5-6 minutes to complete per day. The study will last either 6 or 9 months depending on the brain game training time. The study will be done remotely from the comfort of home using study-provided mobile devices.
$230
Strong English writing and comprehension
Willing to participate for 5 to 9 months
History of dementia or Alzheimer's Disease
Use of video games for more than 2 hours/week over the previous 2 years
Testing a Biosocial Model of Borderline Personality Features in Youth
In this study, we hope to better understand the neural mechanisms underlying risk for Borderline Personality Disorder (BPD) in adolescent girls. BPD is a condition that is usually found in adults. However, it may be possible to identify risk for the disorder before adulthood. Understanding who is at risk for BPD early in development is important in order to develop preventative interventions.
There will be a total of three visits - one main visit and two follow-ups. Participants will be completing questionnaires, participating in a parent-child observation task, and children will be doing an EEG assessment during the first visit. Participants will be asked to complete questionnaires and participate in a parent-child observation task during the follow-up visits.
$100
Girls
With or without a current or past history of mental health disorder
Fluent in English
Diagnosis of intellectual or developmental disabilities (e.g., Autism, Asperger's) , or any psychotic disorders (e.g., schizophrenia, bipolar disorder)
Males
Not fluent in English
PSCI 21-026 A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)
A clinical trial for adults with Muscle Invasive Bladder Cancer. The study is looking at alternative treatments for those persons who cannot tolerate certain forms of chemotherapy.
This protocol contains two portions. The safety run in (SRI) and the main portion of the trial. The SRI will take place over three cycles of treatment prior to having cystectomy or 9 cycles if you have had a previous cystectomy. The main study will have the same schedule of activities. The only difference between the two is the SRI will look at how safe the drug combinations are and the main trial will look at how effective they are on treating muscle invasive bladder cancer.,
body weight above 30kg/66 pounds
history or an organ transplant
inflammatory bowel disease
Walking through the forests of the future: Using data-driven iVR to visualize forests under climate change
We used a combination of ecological modeling, procedural modeling, and virtual reality to provide an embodied experience of “walking through the forests of the future”. This study will provide empirical evidence of the effectiveness of this immersive experience based on users’ feedbacks on different kinds of tools we developed.
undergraduate or graduate students at Penn State University who are older than 18.
participants should be healthy (without contagious disease)
people who are cognitively impaired
people who have contagious disease
PSCI 21-038 Phase Ib Study of Brigatinib Plus Bevacizumab in Patients with ALK-rearranged Non-Small Cell Lung Cancer (NSCLC)
Clinical trial on the treatment of persons who are diagnosed with Lung Cancer.
Participants in this study will undergo screening tests and procedures to determine whether you are eligible to participate with the research study. If you meet the requirements to participate with the study, you be given Brigatinib by mouth each day for 7 days. If you do not experience any intolerable side effects while taking Brigatinib, you will receive an increased dose starting on Day 8 and take Brigatinib continuously each day thereafter. Bevacizumab will be given intravenously (IV) on Day 8 in combination with Brigatinib. The first 28 days of treatment is called Cycle 1. Starting Cycle 2 and thereafter, one cycle will consist of 21 days. Bevacizumab will be given on Day 1 every 21 days starting Cycle 2. Participation is expected to last until your disease worsens or you decide you no longer want to participate in the study. There will be a follow-up visit within 30 days of treatment discontinuation. The study team will check in with you every three months after this final visit to see how you are doing. If you decide to take part, this is what will happen: Since we are looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects in participants that have Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLS), not everyone who participates in this research study will receive the same dose of the study drug. The dose you get will depend on the number of participants who have been enrolled in the study before you and how well they have tolerated their doses. If you take part in this research study, you will be given a drug diary. You will be asked to document information in the drug diary about the study drug you are being asked to take. If you take part in this research, study you will be given a study calendar. Information about what to expect during and between study visits will be included in the study calendar.
major surgery in the last 30 days
heart attack or stroke in the last 6 months
Insulitis, Inflammation, Dietary intake and Omega-3 Biostatus of Youth with Partial Remission of Type 1 Diabetes
Only 50% of patients with type 1 diabetes (T1D) recover insulin secretion function after 3 months of initial diagnosis, and this phase is called partial remission (PR) of T1D, also called "Honeymoon phase". During this PR phase of T1D, patients recover the ability to secrete more than 50% of their insulin secretion function. This phase of PR typically lasts no longer than 6 or up to12 months, and has been frequently defined as requiring exogenous insulin below 0.5 units per kilogram per day, and hemoglobin A1C is typically below 7.5%. Most recently the use of a coefficient called IDAA1C ≤ 9 has became more accepted as the methodology to determine the development of partial clinical remission of T1D (honeymoon phase). Prior data published by the SEARCH study (national epidemiological study) showed that youth with prolonged honeymoon phase had higher intake of omega -3 fatty acids, vitamin D intake and leucine intake than those youth without prolonged honeymoon phase of T1D. Currently, there are not approved medications to prolong this phase of partial remission of type 1 diabetes, however inducing PR in youth with T1D could potentially decrease the risk of multi-organ damage caused by chronic severe hyperglycemia associated to the chronic hyperglycemia related to T1D. We aim to perform a case- multiple control study between youth with prolonged partial remission phase of T1D after one year of diagnosis, and compare these youths with multiple controls matched by age, gender, race, and puberty stage to study the potential protective factors associated to the development of prolonged partial remission of T1D.
Participants will be approached at their routine Pediatric diabetes clinic appointment. If participants agrees to be in the research, informed consent/assent will be reviewed and signed by all parties. Participant's parent/guardian will be asked to complete a questionnaire. The participant's glucose machine/insulin pump will be downloaded for study purposes. Participant will undergo a fingerstick and a blood draw to collect specific lab values as outlined in the consent.
$35.00
Age 1-17 years old, any gender
Attendance to the Pediatric diabetes clinic at Penn State Health in Hershey, PA
Most recent hemoglobin A1C below 7.5%
History of seafood allergies and/or milk/dairy related allergies
Medical conditions (such as severe cerebral palsy, etc.) that could make patients unable to communicate with the study team
Existence of other autoimmune diseases in addition to T1D requiring regular treatment with immunosuppressive or anti-inflammatory treatment
Diagnosis of type 2 diabetes, monogenic diabetes (MODY), secondary diabetes, pregnancy, compromised kidney function, or liver diseases
A Phase II/III Trial of De-intensified Radiation Therapy for Patients with Early-Stage, P16 Positive Oropharyngeal Cancer (NRG-HN005) (PSCI# 20-011)
The purpose of the first part of this study is to compare the usual treatment of a standard-dose radiation given over 6 weeks with cisplatin chemotherapy to a reduced-dose radiation given over either 6 weeks with cisplatin or 5 weeks with the immunotherapy drug, nivolumab. A lower dose of radiation as compared to the usual radiation treatment dose could be as effective in lengthening the time without your cancer getting worse. Nivolumab with reduced-dose radiation may or may not be as effective in lengthening the time without your cancer getting worse. This study will help the study doctors find out if this different approach is the same or worse than the usual approach.
The purpose of the first part of this study is to compare the usual treatment of a standard-dose radiation given over 6 weeks with cisplatin chemotherapy to a reduced-dose radiation given over either 6 weeks with cisplatin or 5 weeks with the immunotherapy drug, nivolumab. A lower dose of radiation as compared to the usual radiation treatment dose could be as effective in lengthening the time without your cancer getting worse. Nivolumab with reduced-dose radiation may or may not be as effective in lengthening the time without your cancer getting worse. This study will help the study doctors find out if this different approach is the same or worse than the usual approach.
Patients must have clinically or radiographically evident measurable disease at the primary site or at nodal stations
P16-positive based on local site immunohistochemical tissue staining
Zubrod Performance Status of 0-1 within 14 days prior to registration
Only English, Spanish, or French speaking patients are eligible to participate as these are the only languages for which the mandatory dysphagia-related patient reported instrument (MDADI) is available
Recurrent disease
Definitive clinical or radiologic evidence of metastatic disease or adenopathy below the clavicles
Cancers considered to be from an oral cavity site or the nasopharynx, hypopharynx, or larynx, even if p16-positive, or histologies of adenosquamous, verrucous, or spindle cell carcinomas
Carcinoma of the neck of unknown primary site origin (T0 is ineligible, even if p16-positive)
Asymmetric neurodegeneration of central olfactory system in early-stage Parkinson’s disease
This research is being done to study the deterioration of the central olfactory system (sense of smell system) in the brains of patients diagnosed with H&Y stage 1 or 2 Parkinson’s disease compared to that of healthy volunteers.
In this study, you will receive a clinical evaluation and an MRI examination. After that, you will be followed every 12 months for up to 4 years.
up to a total of $250.00.
Cognitively-normal H&Y stage 2 PD patients. H&Y stage 2, as defined by an exam in the practically defined “off” state, and have a diagnosis of PD at the age of 59 or younger. 1st visit prior to age 68
Healthy participants between ages 40-67 at their first visit.
Able and willing to provide informed consent
Fluent in written and spoken English
Dementia
Previous antipsychotic or anti-dopamine drug therapy
Traumatic head injury
Other neurological diseases or disorders
Effects of acid sensing ion channels blockade with amiloride on exercise pressor reflex in patients with peripheral artery disease
The purpose of the study is to determine the effects of amiloride on the blood pressure response during exercise, and exercise tolerance in patients with PAD and healthy controls.
There will be 3 in-person visits. You will take a capsule of amiloride or placebo before visits 2 and 3 and blood pressure, heart rate and other physiological measurements will be recorded.
You will receive $25 per hour for your participation in this research study
Any race or ethnicity
Healthy: Free of acute medical conditions
PAD: Diagnosis of PAD, no pain at rest
Resting blood pressure of 150/100 or higher
Already taking amiloride
Recent heart attack or epilepsy
Peripheral neuropathy
GLNE 007 Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas
The purpose of this study is to see if stool or blood can be used to determine whether or not a patient has any colon polyps or colon cancer. This study will compare these biological samples (blood, urine, stool) to any colonoscopy or surgery a patient has to see if the outcome could be predicted.
Subjects with Colon Cancer or Adenoma
OR subjects undergoing colonoscopy screening
HIV/Hepatitis
Have had or are receiving chemotherapy or radiation
Have had surgery for your colon cancer
Cognitive Impairment
Sound Symbolism and Aphasia
Sound symbolism is the idea that the sound of a word alone can convey its meaning. Aphasia is a language impairment, occurring most often as a result of a stroke. There is some evidence that sound-symbolic language is preserved in stroke patients. Studies in this protocol will investigate the extent to which this is so, and whether sound-symbolic language could be a rehabilitation strategy for aphasia.
We will ask you to listen to real words and non-words, or look at pictures of objects, and make judgements about them. We may also ask you to complete some tests of language ability. The total time commitment may be up to four hours but will be split into two sessions.
Amount varies depending on the study
Must have English as your first language
Must have normal or corrected-to-normal vision
Must report normal hearing
May have a recent diagnosis of aphasia following a stroke
Bilingual persons may be excluded from some studies
Minors under the age of 18
Identifying and Predicting Inflection Points in Human-Agent Action Teams Using Relational Event Modeling
The purpose of this study is to better understand how human teams with non-human virtual agent team members operate and function.
If you agree to be in this study, you will be fitted to sensors that will measure your neurophysiological (i.e., brain, cardiac, and respiratory) signals while you complete group tasks in person or in virtual reality. This interaction will be recorded and coded. You will also be asked to complete several questionnaires about your demographics, behaviors, and emotions.
$40
English-speaking
Willing/able to travel to Penn State University Park location research site
No cardiovascular, metabolic, or neurological condition
Willing to wear EEG sensors
Report or diagnosis of a neurological injury or disorders related to cardiovascular-respiratory, metabolic or brain function
Cannot speak or read English
Unable to provide informed consent
Not willing to wear EEG sensors
Characterizing Physical Interactions Used to Correct Robot Errors for Learning from Demonstration
The purpose of this research study is to learn about how humans provide corrections to robot movements when the robot makes mistakes while performing a task. Understanding the intent of humans can inform how we incorporate the information provided by that interaction into machine learning algorithms that improve the robot’s task performance in future.
Participants will observe the robot performing three different tasks. The robot will place a peg in a hole, pickup and pour a cup, and draw and erase an image on a whiteboard. The robot may or may not make mistakes while performing these tasks. Mistakes may be minor or may be significant such as colliding with an object or the work table. Participants will be asked to correct the robot’s mistake by moving the robot arm or stopping the task execution altogether by hitting a red stop button. After observing the robot perform each task several times, you will be asked to demonstrate a new task to the robot. The robot will then try to replicate your demonstration and you may choose to provide corrections to improve the robot’s execution of the task anytime you think it is making a mistake or not performing well enough.
20
Upper limb injuries
Understanding Practices on Social Network Sites and Social Relationships
Social network site (SNS) use has been very integrated into our daily practices. The distinctions between offline and online social relationship management become blurred with the mediation of SNSs. We are interested in how people perceive and use SNS and engage in social relationship management, such as self-disclosure or privacy management. Users may appropriate technological features to meet their own needs and such practices may be different from how others use the sites. The discrepancy of usage may in turn influence social relationship maintenance.
18 years and older
Below 18 years old